scholarly journals Smartphone remote monitoring app to follow-up colorectal cancer survivors: a requirement analysis (Preprint)

2020 ◽  
Author(s):  
Seyed Mohammad Ayyoubzadeh ◽  
Mohammad Shirkhoda ◽  
Sharareh R. Niakan Kalhori ◽  
Niloofar Mohammadzadeh ◽  
Somayyeh Zakerabasali

BACKGROUND Colorectal survivors face multiple challenges after discharge. eHealth may potentially support them by providing tools such as smartphone apps. They have lots of capabilities to exchange information and could be used for remote monitoring of these patients. OBJECTIVE In this study, we addressed the required features for apps designed to follow-up colorectal cancer patients according to survivors' and clinical experts' views. METHODS A mixed method study was conducted. Features of related apps were extracted through the literature; the features were categorized and then they were modified. A questionnaire is designed containing the features listed and prioritized based on the MoSCoW (Must have, should have, could have, won’t have) technique and an open question for each category. The link to the questionnaire was shared among clinical experts in Iran. The answers were analyzed using CVR (Content validity ratio) and based on the value of this measure, the minimum feature set of a monitoring app for colorectal cancer patient’s follow-up was addressed. Also, a telephone interview with colorectal survivors was conducted to collect their viewpoints regarding a remote monitoring system for colorectal cancer cases. RESULTS The questionnaire contained ten sections evaluating nine categories of features. Eighteen experts filled the questionnaire. the minimum features of the app identified as patient information registration, sign and symptoms monitoring, education, reminders, and patient evaluation (0.42<CVR<0.85). Features including physical activity, personalized advice, and the social network did not get the minimum score (-0.11<CVR<0.39). Nine colorectal cancer survivors were interviewed. Information registration, sign and symptoms monitoring, education, and personalized advice were the features with high priority from the survivors’ perspective. Scheduling, shopping, and financial support features were emphasized by survivors in the interview. CONCLUSIONS The requirements set could be used for designing an app for the targeted population. and/or patients affected by other cancers. As the views of both sides of survivors as clinical experts were considered in this study, the remote system may fulfill the need for follow up of survivors more strongly. This eases the patient and health care providers’ communication and interaction CLINICALTRIAL

JMIR Cancer ◽  
10.2196/18083 ◽  
2020 ◽  
Author(s):  
Seyed Mohammad Ayyoubzadeh ◽  
Mohammad Shirkhoda ◽  
Sharareh R. Niakan Kalhori ◽  
Niloofar Mohammadzadeh ◽  
Somayyeh Zakerabasali

2015 ◽  
Vol 42 (3) ◽  
Author(s):  
Nikki Hawkins ◽  
Zahava Berkowitz ◽  
Juan Rodriguez ◽  
Jacqueline Miller ◽  
Susan Sabatino ◽  
...  

2019 ◽  
Vol 21 (10) ◽  
pp. 1440-1440
Author(s):  
R. Vera ◽  
J. Aparicio ◽  
F. Carballo ◽  
M. Esteva ◽  
E. González-Flores ◽  
...  

1996 ◽  
Vol 3 (2) ◽  
pp. 113-119 ◽  
Author(s):  
Barbara L. Andersen

Women treated for gynecologic cancer represent approximately 45% of cancer survivors. Many report significant sexual difficulties during follow-up, and data suggest these difficulties are direct consequences of their cancer treatments. Health care providers can identify at the time of initial therapy those women who will be at greater risk for problem development. Clinical observations are provided on the development of sexual problems for these women as they attempt to resume sexual intercourse, and the psychologic and behavioral therapies that can be used for treatment are discussed.


2009 ◽  
Vol 24 (S2) ◽  
pp. 472-479 ◽  
Author(s):  
David A. Haggstrom ◽  
Neeraj K. Arora ◽  
Paul Helft ◽  
Marla L. Clayman ◽  
Ingrid Oakley-Girvan

2021 ◽  
Vol 9 (C) ◽  
pp. 170-173
Author(s):  
Idaliya Rakhimova ◽  
Talgat Khaibullin ◽  
Yerbol Smail ◽  
Zhanar Urazalina ◽  
Vitalii Koval`chuk ◽  
...  

BACKGROUND: Patients with heart failure (HF) and implanted heart devices constitute a vulnerable category during the coronavirus disease –2019 (COVID-19) pandemic. The remote monitoring function allows the physician to detect atrial fibrillation (AF) in these patients and to prevent thromboembolic complications by prescribing anticoagulants. Under quarantine conditions, such patients can receive fully remote consultation and treatment, which will protect them from the risk of infection, and also reduce the burden on medical institutions. CASE REPORT: A 56-year-old man presented to the clinic with shortness of breath when climbing the second floor, moderate non-specific fatigue, general weakness, and a decrease in exercise tolerance. The patient received standard treatment for HF for at least 3 months (ACEI, beta blockers, MR antagonists, and loop diuretics) in individually selected adequate doses. ECG on admission showed a QRS of 150 ms, left bundle branch block (LBBB). Echo showed dilatation of all heart chambers, diffuse hypokinesis of the walls with akinesis of the apical, middle anterior LV segments, as well as hypokinesis of the basal, middle apical, and anterior septal segment of the LV. The ejection fraction was reduced to 35%. RV function is reduced. After a detailed discussion with the team, it was decided to do implantation of a cardioverter-defibrillator with resynchronization function, equipped with remote monitoring (Biotronik, and Home monitoring). Date of implantation is June 19, 2014. Due to the fact that the patient was connected to the remote monitoring system, May 5, 2020, he was diagnosed with asymptomatic AF. The episode lasted 1 min 22 s. On the following days of monitoring, episodes of AF were also recorded. The duration of the episodes ranged from a few seconds to 12 h/day. The patient received a doctor’s consultation through phone call, his risk of stroke was four when assessed using the CHA2DS2VASc scale. In treatment, it was recommended to add antiarrhythmic drugs (amiodarone 600 mg a day) and oral anticoagulants (rivaroxaban 20 mg × 1 time/day). Later, periodic IEGM showed absence of AF. CONCLUSION: In the context of the COVID-19 pandemic, health-care providers should rethink their approach to managing patients with implanted heart devices. Modern cardiovascular implantable electronic devices allow the physician to monitor the status of patients and immediately respond to situations requiring a change in treatment. Consultations can be carried out completely online.


2020 ◽  
Vol 29 (10) ◽  
pp. 1557-1563 ◽  
Author(s):  
Sungwon Yoon ◽  
Teck Beng Chua ◽  
Iain Beehuat Tan ◽  
David Matchar ◽  
Marcus Eng Hock Ong ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document